Cantor Fitzgerald initiated coverage on Corvus Pharmaceuticals with a new price target

5/27/21 7:27:33 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Cantor Fitzgerald initiated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $10.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRVS

Date	Price Target	Rating	Analyst
1/2/2025	$11.00	Buy	H.C. Wainwright
8/18/2023	$7.00	Outperform	Oppenheimer
12/3/2021	$5.00 → $8.00	Overweight	Cantor Fitzgerald
12/1/2021	$8.00	Buy	Jefferies
8/3/2021	$4.00 → $3.50	Neutral	Mizuho
7/16/2021	$9.50 → $6.00	Buy	HC Wainwright & Co.